The five year contract, supposed to be an Indefinite Delivery/Indefinite Quantity (IDIQ) award, also includes manufacturing of clinical grade iPSC-derived cell types.
Lonza Walkersville president Lukas Utiger said, "Our goal is to help cell therapy developers navigate the complexities of process optimization and cGMP-compliant manufacturing for clinical trials and beyond."
Due to the potential of the induced pluripotent stem cells to become any cell type in the body, iPSC technology can be used to develop cell transplantation therapies for the treatment of degenerative diseases such as diabetes, Parkinson’s Disease and a number of cardiovascular diseases.